H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Revance to $42 from $29 and keeps a Buy rating on the shares. The anlasyt reviewed over 100 social media posts made by both Daxxify injectors and patients across different platforms, which increased the firm’s confidence in Daxxify’s commercial prospects.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVNC: